A repeat expansion test measures how many times a short DNA sequence is repeated at a specific gene or chromosome location. Repeats such as CAG, CGG, CTG, GAA, and other motifs occur normally in human DNA. Disease can develop when one repeat tract becomes longer than the stable range, changes gene expression, produces a toxic RNA, or creates an abnormally long protein segment. Huntington disease, fragile X–related conditions, myotonic dystrophy, Friedreich ataxia, and several spinocerebellar ataxias are well-known examples.
Repeat expansions need specialized testing because routine short-read sequencing and standard gene panels may fail to detect or size them accurately. The laboratory may use fluorescent PCR with fragment analysis, repeat-primed PCR, Southern blotting, methylation analysis, long-range PCR, or long-read sequencing. Results are reported as repeat numbers, size categories, methylation status, or a pattern consistent with an expansion. The meaning is gene-specific: the same repeat count can be normal in one gene and disease-associated in another.
- A repeat expansion result must be interpreted for the exact gene, because normal, intermediate, premutation, and disease ranges differ by condition.
- Larger expansions often increase disease risk, but repeat number may not predict an individual’s exact age of onset or severity.
- Intermediate or reduced-penetrance alleles may not cause disease in the tested person yet can be unstable when passed to children.
- A negative sequencing panel may not exclude a repeat disorder unless the report specifically states that the relevant expansion was assessed.
- Predictive testing for an adult-onset repeat disorder benefits from genetic counseling, especially when no preventive treatment can eliminate the risk.
Table of Contents
- Why Repeat Expansions Need Special Testing
- CAG, CGG, CTG, and Other Repeat Disorders
- Laboratory Methods for Sizing Expansions
- How Repeat Counts Are Classified
- Inheritance, Anticipation, and Mosaicism
- Positive, Negative, and Inconclusive Results
- Testing Accuracy and Important Limitations
- Who May Be Tested and What Happens Next
Why Repeat Expansions Need Special Testing
A tandem repeat is a short DNA motif copied back-to-back. Most repeat tracts remain within a stable size range and cause no health problem. Some loci are unstable, however, and can gain repeat units during egg or sperm formation, early development, or cell division throughout life.
Different expansions harm cells in different ways. A CAG repeat within a protein-coding region may produce an abnormally long glutamine tract, as in Huntington disease and several spinocerebellar ataxias. A CGG expansion in the FMR1 gene can cause abnormal methylation and silence the gene when the expansion reaches the full-mutation range. A CTG expansion in DMPK is transcribed into RNA that traps RNA-binding proteins and disrupts splicing in myotonic dystrophy type 1. A GAA expansion in FXN reduces gene expression in Friedreich ataxia.
Standard short-read sequencing typically creates fragments around 100–300 bases long. A large repeat may exceed the read length, contain few unique landmarks, and be difficult to align to the reference genome. Capture-based exome tests may not cover the repeat at all. A report that says “no pathogenic sequence variants found” can therefore coexist with an undetected expansion.
Even when software flags evidence of an expansion, clinical confirmation may be needed to determine the repeat number, allele structure, interruptions, methylation, or mosaicism. The relevant question is not simply whether sequencing was performed, but whether the laboratory validated detection of the named repeat disorder.
The test design usually targets one locus or a defined panel of repeat loci. A Huntington disease assay focuses on the CAG tract in HTT. A fragile X assay examines the CGG repeat in FMR1 and may assess methylation. A broad neurologic repeat panel can evaluate multiple ataxia, neuromuscular, and dementia-associated loci. Because new repeat disorders continue to be discovered, panel content and analytical methods can differ substantially among laboratories.
A dedicated Huntington disease genetic test or other disease-specific assay often gives a more definitive repeat size than a general sequencing test. The ordering clinician should match the method to the symptoms, family history, ancestry, and suspected condition.
CAG, CGG, CTG, and Other Repeat Disorders
Repeat motifs are often discussed as if the three letters define the disease. In reality, location and gene function are just as important as the motif.
| Gene or locus | Repeat | Associated condition | Special interpretive feature |
|---|---|---|---|
| HTT | CAG | Huntington disease | Intermediate and reduced-penetrance ranges are recognized |
| FMR1 | CGG | Fragile X syndrome, FXTAS, FXPOI | Premutation and full-mutation alleles have different clinical effects; methylation matters |
| DMPK | CTG | Myotonic dystrophy type 1 | Large expansions and tissue mosaicism can make exact sizing difficult |
| CNBP | CCTG | Myotonic dystrophy type 2 | Complex repeat structure may be reported as expanded rather than precisely sized |
| FXN | GAA | Friedreich ataxia | Usually requires two expanded alleles, though sequence variants can occur on the other allele |
| C9orf72 | GGGGCC | ALS and frontotemporal dementia | Large expansions can be hard to size exactly with routine PCR |
| RFC1 | AAGGG and related motifs | CANVAS and late-onset ataxia | Motif identity and biallelic status are important |
CAG disorders include Huntington disease, dentatorubral-pallidoluysian atrophy, spinal and bulbar muscular atrophy, and several spinocerebellar ataxias. The repeat threshold differs by gene. A count that is clearly pathogenic in HTT cannot be transferred to ATXN1, ATXN2, ATXN3, or another ataxia gene.
FMR1 CGG categories are clinically distinctive. A full mutation usually silences FMR1 and causes fragile X syndrome, while premutation alleles are associated with fragile X–associated tremor/ataxia syndrome in some older adults and fragile X–associated primary ovarian insufficiency in some females. Premutation alleles can expand during maternal transmission, with risk influenced by repeat size and stabilizing AGG interruptions.
CTG expansions in DMPK cause a multisystem disorder that can involve muscle weakness, myotonia, cataracts, cardiac conduction disease, respiratory problems, endocrine changes, and other features. Repeat size correlates broadly with phenotype but overlaps extensively among individuals. Blood repeat size may also differ from the expansion in muscle or other tissues.
Some diseases are caused by noncoding repeats, pentanucleotide repeats, hexanucleotide repeats, or complex motifs. The growing list includes recently recognized adult-onset ataxias. A modern repeat panel may be useful when symptoms overlap, but the clinician should verify that the panel contains the suspected newer locus and can distinguish pathogenic motifs from benign alternatives.
Laboratory Methods for Sizing Expansions
No single technique is ideal for every repeat size and locus. Laboratories may combine methods so that one assay detects an expansion and another estimates size or methylation.
Fluorescent PCR and capillary electrophoresis
Primers placed on both sides of a repeat amplify the region. Fluorescently labeled products are separated by size in a capillary instrument. The laboratory converts fragment length into repeat count.
This method works well for normal and moderately expanded alleles that remain amplifiable. Very large or GC-rich expansions may fail to amplify, creating an apparent single allele in a person who actually has one normal and one large expanded allele. That possibility is especially important in FMR1 testing.
Repeat-primed PCR
Repeat-primed PCR uses a primer that binds within the repeat and produces a characteristic ladder or saw-tooth pattern. It can show that an expansion is present even when the full repeat cannot be amplified end to end. It may not provide an exact size for a very large allele, and some assays can struggle with interruptions or alternative motifs.
Triplet repeat-primed PCR is widely used for CAG, CGG, and CTG disorders. Similar designs support tetranucleotide, pentanucleotide, and hexanucleotide expansions. The electropherogram pattern must be interpreted with locus-specific controls and thresholds.
Southern blot and methylation analysis
Southern blotting can evaluate very large expansions and, in selected assays, methylation. It requires more DNA, is labor-intensive, and takes longer than PCR, but it remains valuable for complex FMR1 full mutations, methylation mosaicism, and some large expansions.
Methylation-specific PCR or other methylation methods may provide the needed epigenetic information with less DNA. For fragile X testing, repeat size alone may not fully describe gene silencing and mosaic patterns.
Long-range PCR and long-read sequencing
Long-range PCR uses enzymes and conditions designed to amplify larger fragments. Long-read sequencing can read through many expanded alleles and reveal repeat length, motif composition, interruptions, nearby variants, and methylation on individual molecules. It is increasingly useful for difficult or unresolved cases.
Long-read methods are not yet identical across laboratories. Accuracy can depend on DNA quality, sequencing platform, analysis software, coverage, and the size of the expansion. Some clinical workflows still confirm findings with an established locus-specific assay.
Indirect and complementary methods
Repeat expansions may sometimes be inferred from genome data, linked-marker analysis, or characteristic RNA findings. These approaches can guide further testing but generally do not replace direct clinical confirmation when a diagnosis or predictive result is at stake.
The final report should state whether both alleles were sized, whether an expansion was only detected rather than precisely measured, and whether methylation or interruptions were assessed.
How Repeat Counts Are Classified
Repeat counts are divided into ranges based on observed stability, disease association, and penetrance. The labels vary: normal, intermediate, mutable normal, gray zone, premutation, reduced penetrance, full mutation, or pathogenic expansion.
| Condition and gene | Commonly used categories | Interpretive caution |
|---|---|---|
| Huntington disease, HTT | 26 or fewer normal; 27–35 intermediate; 36–39 reduced penetrance; 40 or more full penetrance | Repeat length influences risk and average onset but cannot predict an exact personal course |
| Fragile X, FMR1 | About 5–44 normal; 45–54 intermediate; 55–200 premutation; over 200 full mutation | AGG interruptions, methylation, sex-related biology, and mosaicism affect risk and phenotype |
| Myotonic dystrophy type 1, DMPK | About 5–34 normal; 35–49 unstable or premutation range; 50 or more disease-associated | Large alleles may be approximate, and blood size may not reflect all tissues |
These ranges are examples, not a universal reference table. Laboratories may use slightly different boundary wording based on current professional standards, assay precision, transcript choice, and evolving evidence. The report’s interpretation should take priority over a general chart.
A result near a boundary may include a measurement uncertainty, such as plus or minus one to several repeats. This matters when the measured count sits at the transition between categories. Repeat interruptions can also alter stability or phenotype without changing the simple count.
For Huntington disease, alleles with 36–39 CAG repeats have reduced penetrance: some people develop symptoms and some do not. Forty or more repeats are generally considered fully penetrant over a normal lifespan, although age of onset varies widely. Juvenile-onset disease is more often associated with very large expansions.
For FMR1, an intermediate allele does not cause fragile X syndrome and usually has limited expansion risk in one generation. A premutation does not usually produce classic fragile X syndrome, but it can cause adult-onset or reproductive conditions and can expand to a full mutation during maternal transmission. A full mutation’s methylation and mosaicism influence expression.
For many newer repeat diseases, thresholds are less settled. Some laboratories report “pathogenic expansion detected” without an exact count when size exceeds the validated range. The absence of a precise number does not make the finding less clinically important if the expansion is clearly above the disease threshold.
Inheritance, Anticipation, and Mosaicism
Repeat disorders can show dynamic inheritance: the repeat count may change between parent and child. Expansion risk often depends on the gene, parent of origin, allele size, repeat purity, and interruptions.
Anticipation describes a tendency for symptoms to begin earlier or become more severe in successive generations, often because the repeat expands. It is well recognized in Huntington disease, myotonic dystrophy, and several ataxias, but the direction and magnitude of instability differ by condition.
In Huntington disease, larger expansions are often associated with paternal transmission, especially for very large juvenile-onset alleles. In myotonic dystrophy type 1, severe congenital disease is most often associated with maternal transmission. In fragile X, a premutation expands to a full mutation through maternal transmission; paternal premutations are passed to daughters as premutations rather than becoming full mutations through that transmission.
Intermediate alleles can matter mainly because of future instability. A person may be unaffected but have a repeat that can expand in descendants. Counseling should separate the tested person’s health risk from reproductive and family implications.
Mosaicism means not every cell has the same repeat size or methylation pattern. It can arise because unstable repeats continue changing after fertilization or during life. A laboratory may see a distribution of fragment sizes rather than one sharp allele.
Somatic expansion can occur in certain tissues over time. In Huntington disease, expansion within vulnerable tissues is being studied as a contributor to disease timing. In myotonic dystrophy, repeat sizes can differ substantially among blood, muscle, and other tissues. A blood result confirms the germline disorder but may not mirror the largest expansion in the body.
Mosaicism can complicate prenatal testing, phenotype prediction, and exact sizing. Reports may describe size mosaicism, methylation mosaicism, or both. The clinical meaning should be discussed with a genetics professional familiar with the specific condition.
Positive, Negative, and Inconclusive Results
A positive result means the laboratory found an expansion within a category associated with the condition or a related risk state. The report should name the gene, repeat motif, measured or estimated sizes, classification, inheritance, and important limitations.
A diagnostic positive result in a person with compatible symptoms can confirm the molecular diagnosis. A predictive positive result in an asymptomatic adult may show that the person is expected or more likely to develop an adult-onset condition. The psychological and family impact can be substantial even when the timing remains uncertain.
A premutation or intermediate result is not equivalent to a full disease-causing expansion. It may indicate reproductive instability, adult-onset risk, or a need for condition-specific monitoring. The report should avoid collapsing these distinct categories into the word “positive.”
A negative result means no expansion was found within the assay’s reportable range. Its strength depends on the clinical question:
- If a person was tested for a known familial expansion and the assay reliably measured both alleles, the result can be strongly reassuring for that familial condition.
- If a broad ataxia panel was negative, other repeat loci, sequence variants, copy-number changes, mitochondrial disorders, acquired causes, or newly discovered genes may remain possible.
- If only standard exome sequencing was negative, a repeat disorder may not have been assessed at all.
An inconclusive result can occur when one allele fails to amplify, the expansion exceeds accurate sizing limits, the signal pattern is atypical, mosaicism is complex, or the specimen is inadequate. Additional repeat-primed PCR, Southern blot, methylation analysis, parental testing, or long-read sequencing may resolve it.
Some reports identify two different expansions or a repeat expansion plus a sequence variant. In recessive disorders such as Friedreich ataxia, one expanded allele and one pathogenic sequence variant can cause disease. Complete gene analysis may therefore be needed when only one expansion is detected in a person with a strong phenotype.
Testing Accuracy and Important Limitations
Clinical repeat assays are usually highly accurate within their validated size range, but large and complex alleles challenge precise measurement. Accuracy should be considered separately for detecting an expansion, estimating size, identifying interruptions, and measuring methylation.
PCR can preferentially amplify the smaller allele. A very large allele may be missed by flanking PCR unless repeat-primed PCR or another method is included. GC-rich FMR1 repeats are particularly difficult. Southern blot can detect large alleles but may provide a size range rather than a single repeat count.
Technical limits include:
- uncertainty of several repeats for very large alleles;
- inability to distinguish interruption patterns;
- poor detection of low-level mosaic alleles;
- allele dropout from a variant under a primer;
- limited coverage of newly discovered repeat loci;
- difficulty identifying alternative pathogenic motifs;
- DNA degradation or insufficient high-molecular-weight DNA;
- uncertain thresholds for newly described disorders.
Biological limits are just as important. Repeat size rarely predicts a person’s exact future. Sex, parent of origin, interruptions, other genetic modifiers, environment, somatic instability, and chance all influence phenotype. Two relatives with similar repeat counts can have different ages of onset and severity.
A consumer ancestry or wellness test should not be used to diagnose a repeat disorder unless it is specifically validated for that locus and confirmed clinically. Many consumer arrays do not measure expansions directly. Raw-data interpretations can mistake nearby marker variants for the expansion itself.
Laboratory reports can also change as thresholds and disease associations evolve. Keep the original report and ask about reinterpretation when symptoms progress, a new repeat disorder becomes relevant, or a prior test used an older limited panel.
Who May Be Tested and What Happens Next
Repeat expansion testing may be diagnostic, predictive, carrier-related, prenatal, or part of reproductive planning.
Diagnostic testing is considered when symptoms and family history suggest a repeat disorder. Examples include progressive chorea, ataxia, myotonia, unexplained muscle weakness, early cataracts, developmental disability with fragile X features, premature ovarian insufficiency, tremor/ataxia in an older FMR1 premutation carrier, or combined ALS and frontotemporal dementia features.
Predictive testing in a healthy adult requires careful consent. For Huntington disease and similar untreatable adult-onset disorders, many centers use a structured protocol that includes genetic counseling, neurologic or medical review, psychological assessment, discussion of insurance and privacy, and a plan for disclosing results. Testing should be voluntary and free from family pressure.
Predictive testing of children is generally avoided for adult-onset conditions when no childhood medical benefit exists. Testing may be appropriate when symptoms are present or when the result changes childhood care. Fragile X and some multisystem repeat disorders require condition-specific judgment.
Before testing, clarify:
- the exact condition and repeat locus being assessed;
- whether the assay sizes both alleles;
- whether repeat-primed PCR, methylation, or Southern blot is included;
- what intermediate or premutation findings could mean;
- whether results affect children, siblings, parents, or reproductive plans;
- how uncertain or unexpected findings will be handled.
Blood is the most common sample and usually requires no fasting. Saliva or cheek samples may be accepted, but high-quality blood DNA can be preferable for complex sizing. Prenatal samples require strict maternal-cell contamination checks and condition-specific interpretation.
After a pathogenic result, care may include neurology, cardiology, reproductive medicine, developmental services, rehabilitation, or other specialists. Family members should generally receive targeted testing for the known expansion rather than a broad search. A familial variant genetic test can be adapted to the repeat disorder and laboratory method.
A negative result may lead to a wider repeat panel, exome or genome sequencing with repeat-aware analysis, mitochondrial testing, structural-variant testing, or evaluation for non-genetic causes. Long-read sequencing is increasingly useful when conventional testing leaves a strong repeat-disorder suspicion unresolved.
References
- The additional diagnostic yield of long-read sequencing in undiagnosed rare diseases: a systematic review 2025 (Systematic Review)
- The role of long-read sequencing in unraveling genetic complexity and advancing precision medicine 2025 (Review)
- Spinocerebellar ataxia 27B: A novel, frequent and potentially treatable ataxia 2024 (Review)
- Recent advances in CGG repeat diseases and a proposal for a new concept of repeat motif-phenotype correlation 2023 (Review)
- Huntington’s disease: diagnosis and management 2022 (Review)
- Laboratory testing for fragile X, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG) 2021 (Technical Standard)
Disclaimer
Repeat expansion testing can reveal serious inherited and predictive information for the tested person and relatives. Results, especially intermediate, premutation, reduced-penetrance, mosaic, or predictive findings, should be reviewed with a genetics professional familiar with the specific disorder. A repeat count cannot predict an individual’s exact age of onset, symptoms, or disease course.
